Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Traws Pharma, Inc. ( Traws, we, or the Company ) is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health.
The business is unprofitable at the operating level (-640.68% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 1134.5% YoY with margins expanding 62356.7pp.
Negative free cash flow of -$21M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$3M
▲ +1134.5% YoY
Net Income (TTM)
-$19M
▲ +105.5% YoY
Op. Margin
-640.68%
▲ +62356.7pp YoY
ROIC
-484.05%
Cash Flow & Balance Sheet
FCF (FY)
-$21M
▲ +37.9% YoY
Op. Cash Flow (TTM)
-$15M
▲ +39.0% YoY
Net Debt
-$3M
Net Cash Position
Cash & Equiv.
$3M
5Y CAGR: +64.6%
Continue Research